II. Mechanism
- Mu-Opioid receptor Agonist
- Norepinephrine reuptake inhibitor
III. Indications
- Moderate to severe acute pain
IV. Contraindications
- Severe renal Impairment
- Severe hepatic Impairment
V. Efficacy
- As effective as Oxycodone
- Less Nausea, Vomiting and Constipation than Oxycodone
VI. Drug Interactions
- Serotonin Syndrome risk
VII. Adverse Reactions
- Seizures
- Anaphylactoid Reaction
- Respiratory Depression
VIII. Preparations
- Schedule II Controlled Substance
- Immediate release
- Tapentadol 50-100 mg orally every 4-6 hours as needed (up to 600 mg/day)
- Decrease dose to 50 mg every 8 hours if moderate hepatic Impairment
- Extended release
- Tapentadol XR 50 mg orally twice daily (and titrate up to 250 mg twice daily)
- May start higher if transitioning from other Opioids
IX. References
- Tarascon pharmacopeia (2013)
- Hartrick (2011) CNS Drugs 25(5): 359-70 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| nucynta (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| NUCYNTA 100 MG TABLET | $13.17 each | |
| NUCYNTA 50 MG TABLET | $8.47 each | |
| NUCYNTA 75 MG TABLET | $9.91 each | |
| NUCYNTA ER 100 MG TABLET | $16.90 each | |
| NUCYNTA ER 150 MG TABLET | $21.80 each | |
| NUCYNTA ER 200 MG TABLET | $27.62 each | |
| NUCYNTA ER 250 MG TABLET | $34.52 each | |
| NUCYNTA ER 50 MG TABLET | $9.14 each | |
Ontology: tapentadol (C2001271)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | C523979 |
| SnomedCT | 441757005, 442004000 |
| LNC | LP99218-7, MTHU035629 |
| English | Tapentadol, Tapentadol (product), Tapentadol (substance), TAPENTADOL, tapentadol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol |
| Spanish | tapentadol (producto), tapentadol, tapentadol (sustancia) |
